At the Toronto weight management clinic of Dr. David Macklin, discussions surrounding Ozempic and generics have become commonplace. Patients are increasingly inquiring about the potential cost savings of their medications, highlighting a shift in dialogue, according to Macklin, who heads the Medcan Weight Management Program.
For years, Novo Nordisk held the exclusive patent on semaglutide, the active component in the popular diabetes and weight-loss drugs Ozempic and Wegovy. This patent monopoly resulted in elevated costs as Novo Nordisk was the sole manufacturer of these drugs. Macklin revealed that a monthly supply of Ozempic or Wegovy could range from $300 to $400, with variations based on dosage.
However, the expiration of Novo Nordisk’s patent in Canada and the subsequent loss of market exclusivity in January have paved the way for the introduction of more affordable generic alternatives, not only in Canada but also in other countries like India, where patents recently expired.
Although the specific timeline for the availability of generic versions in Canada remains uncertain, both patients and physicians eagerly anticipate this development, as it promises increased affordability and accessibility of these crucial medications. Macklin emphasized the potential impact of generics in making effective treatments more accessible to individuals grappling with obesity.
Health Canada currently has nine generic semaglutide medications under review for approval, with an estimated timeframe for potential availability in the summer or early fall. The introduction of generics in India saw immediate market entry by several companies upon patent expiry, offering significantly lower prices than the brand-name versions.
The cost of generic drugs in Canada will be influenced by various factors within the country’s drug pricing framework. Analysts predict that with the influx of generics, prices could drop to approximately $100 per month or even lower, presenting substantial savings for consumers.
Patients like Sarah Brooks are eagerly anticipating the arrival of generic alternatives, as the cost of brand-name medications can be prohibitive for many. The availability of generics is poised to alleviate financial burdens and ensure continuity in treatment for individuals like Brooks.
The introduction of more affordable generics is expected to benefit not only individual patients but also the broader healthcare system by reducing costs associated with untreated obesity. Additionally, the potential societal impact of improved access to generics in destigmatizing obesity is a significant consideration.
Dr. Iris Gorfinkel, a family medicine practitioner in Toronto, highlighted the potential overuse and cosmetic motivations behind some patients’ requests for GLP-1 medications. The introduction of generics is expected to address these issues by making the drugs more accessible to those who genuinely require them.
As the landscape of GLP-1 drugs evolves with the emergence of generics, concerns about unauthorized versions and misuse persist. Health Canada has issued warnings about the proliferation of fake or unauthorized drugs, emphasizing the importance of regulatory oversight and affordability in mitigating such risks.
